OBJECTIVE: Type II collagen (CII) is a cartilage-specific protein to which a loss of immune tolerance may trigger autoimmune reactions and cause arthritis. The major T cell epitope on CII, amino acids 259-273, can be presented by several HLA-DRB1 04 alleles in its native or posttranslational glycosylated form. The present study was undertaken to functionally explore and compare CII-autoreactive T cells from blood and synovial fluid of patients with rheumatoid arthritis (RA). METHODS: Peripheral blood was obtained from HLA-DRB1 04-positive RA patients (n = 10) and control subjects (n = 10) and stimulated in vitro with several variants of the CII(259-273) epitope, i.e., unmodified, glycosylated on Lys-264, glycosylated on Lys-270, or glycosylated on both Lys-264 and Lys-270. Up-regulation of CD154 was used to identify responding T cells. These cells were further characterized by intracellular staining for interleukin-17 (IL-17), interferon-γ (IFNγ), and IL-2 by flow cytometry. Synovial T cells from RA patients were investigated in parallel. RESULTS: Multifunctional T cell responses toward all examined variants of the CII(259-273) peptide could be detected in RA patients and, to a lesser extent, also in healthy HLA-matched controls (P < 0.001). In RA patients, a comparison between blood- and joint-derived T cell function revealed a significant increase in levels of the proinflammatory cytokine IFNγ in synovial T cells (P = 0.027). Studies of longitudinally obtained samples showed that T cell responses were sustained over the course of disease, and even included epitope spreading. CONCLUSION: The identification of inflammatory T cell responses to both glycosylated and nonglycosylated variants of the major CII epitope in RA patients suggests that CII autoreactivity in RA may be more common than previously recognized.
OBJECTIVE: Type II collagen (CII) is a cartilage-specific protein to which a loss of immune tolerance may trigger autoimmune reactions and cause arthritis. The major T cell epitope on CII, amino acids 259-273, can be presented by several HLA-DRB1 04 alleles in its native or posttranslational glycosylated form. The present study was undertaken to functionally explore and compare CII-autoreactive T cells from blood and synovial fluid of patients with rheumatoid arthritis (RA). METHODS: Peripheral blood was obtained from HLA-DRB1 04-positive RApatients (n = 10) and control subjects (n = 10) and stimulated in vitro with several variants of the CII(259-273) epitope, i.e., unmodified, glycosylated on Lys-264, glycosylated on Lys-270, or glycosylated on both Lys-264 and Lys-270. Up-regulation of CD154 was used to identify responding T cells. These cells were further characterized by intracellular staining for interleukin-17 (IL-17), interferon-γ (IFNγ), and IL-2 by flow cytometry. Synovial T cells from RApatients were investigated in parallel. RESULTS: Multifunctional T cell responses toward all examined variants of the CII(259-273) peptide could be detected in RApatients and, to a lesser extent, also in healthy HLA-matched controls (P < 0.001). In RApatients, a comparison between blood- and joint-derived T cell function revealed a significant increase in levels of the proinflammatory cytokine IFNγ in synovial T cells (P = 0.027). Studies of longitudinally obtained samples showed that T cell responses were sustained over the course of disease, and even included epitope spreading. CONCLUSION: The identification of inflammatory T cell responses to both glycosylated and nonglycosylated variants of the major CII epitope in RApatients suggests that CII autoreactivity in RA may be more common than previously recognized.
Authors: Eddie A James; Antonis K Moustakas; John Bui; George K Papadopoulos; George Bondinas; Jane H Buckner; William W Kwok Journal: Arthritis Rheum Date: 2010-10
Authors: Marco Frentsch; Olga Arbach; Dennis Kirchhoff; Beate Moewes; Margitta Worm; Martin Rothe; Alexander Scheffold; Andreas Thiel Journal: Nat Med Date: 2005-09-25 Impact factor: 53.440
Authors: Omri Snir; Mary Rieck; John A Gebe; Betty B Yue; Crystal A Rawlings; Gerald Nepom; Vivianne Malmström; Jane H Buckner Journal: Arthritis Rheum Date: 2011-10
Authors: M Londei; C M Savill; A Verhoef; F Brennan; Z A Leech; V Duance; R N Maini; M Feldmann Journal: Proc Natl Acad Sci U S A Date: 1989-01 Impact factor: 11.205
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: U Brunsberg; K Gustafsson; L Jansson; E Michaëlsson; L Ahrlund-Richter; S Pettersson; R Mattsson; R Holmdahl Journal: Eur J Immunol Date: 1994-07 Impact factor: 5.532
Authors: Johan Bäcklund; Stefan Carlsen; Torsten Höger; Björn Holm; Lars Fugger; Jan Kihlberg; Harald Burkhardt; Rikard Holmdahl Journal: Proc Natl Acad Sci U S A Date: 2002-06-27 Impact factor: 11.205
Authors: Tamás Kobezda; Sheida Ghassemi-Nejad; Katalin Mikecz; Tibor T Glant; Zoltán Szekanecz Journal: Nat Rev Rheumatol Date: 2014-01-07 Impact factor: 20.543
Authors: Anca I Catrina; A Jimmy Ytterberg; Gudrun Reynisdottir; Vivianne Malmström; Lars Klareskog Journal: Nat Rev Rheumatol Date: 2014-07-29 Impact factor: 20.543